When Robert F. Kennedy Jr. was confirmed as Secretary of Health and Human Services earlier this year, he pledged to restore honesty, transparency, and scientific rigor to the nation’s public health system. On Sep. 17, the Senate will hold a hearing that will put those promises to the test, as two former Centers for Disease Control and Prevention (CDC) officials return to Capitol Hill to criticize Kennedy’s early reforms.
The hearing, scheduled before the Senate Health, Education, Labor and Pensions Committee, will feature testimony from Susan Monarez, who briefly served as CDC director before being fired, and Debra Houry, a career CDC official who stepped down in protest after Monarez’s departure. Both witnesses are expected to present a version of events that casts Kennedy as heavy-handed and intent on reshaping vaccine policy for political rather than scientific purposes.
Kennedy’s supporters argue that the opposite is true. They view Wednesday’s hearing as the latest effort by entrenched bureaucrats and their political allies to undermine reforms that have been badly needed for years. They say Kennedy is finally confronting the deep institutional failures that led to mistrust, confusion, and policy disasters during the COVID-19 pandemic, and that the backlash from Monarez and Houry proves how resistant the bureaucracy has been to outside accountability.
Monarez was confirmed as CDC director earlier this summer but lasted only a few weeks before Kennedy demanded her resignation. According to her prepared testimony, she will tell senators that Kennedy wanted her to pre-approve vaccine policy, fire senior officials, and defer to his judgment on scientific matters. She claims she refused on principle. Kennedy has already rejected that characterization, stating that Monarez acknowledged in a private meeting that she could not be trusted to carry out his agenda of reform. He has made clear that he is determined to root out what he sees as corruption, conflicts of interest, and politicized science that have damaged the credibility of public health institutions.
Houry, who left the agency after Monarez’s departure, is expected to argue that Kennedy’s changes have endangered the independence of CDC scientists. Her critics argue that she embodies the very culture that led to conflicting pandemic guidance, opaque decision-making, and a decline in public trust. In their view, Kennedy is not undermining science but restoring it, insisting that recommendations be based on transparent review of evidence rather than bureaucratic inertia or pressure from pharmaceutical companies.
At the center of the dispute is Kennedy’s overhaul of the Advisory Committee on Immunization Practices (ACIP), the panel that reviews data and recommends vaccine schedules. Earlier this year, Kennedy dismissed all 17 members of ACIP, citing longstanding concerns about conflicts of interest and lack of genuine debate. He has since appointed a new slate of members, including physicians and researchers who are not tied to the pharmaceutical industry and who have questioned some of the assumptions underlying past vaccine mandates. Critics describe them as skeptics, but Kennedy’s allies say they are precisely the independent voices needed to restore integrity.
The stakes are high. ACIP recommendations determine not only which vaccines are encouraged for children and adults but also which are covered by insurance, provided by schools, and supported by federal programs. Under Kennedy’s leadership, the panel is preparing to review recommendations for COVID-19, RSV, measles, and other vaccines. For the first time in decades, those discussions may not be foregone conclusions.
Supporters of Kennedy argue that the furious response from former officials shows how much power has been concentrated in a small circle of public health insiders. They point out that Monarez and Houry have longstanding ties to agencies, academic institutions, and outside groups that have benefited from federal funding and close collaboration with pharmaceutical companies. They argue that Kennedy’s efforts to shake up the status quo threaten not just individual careers but an entire ecosystem of influence built over decades.
Kennedy has repeatedly said that his goal is not to dismantle the CDC but to make it functional again. He has emphasized transparency, promising to release data underlying agency recommendations and to open advisory committee meetings to greater public scrutiny. He has also pledged to broaden debate, allowing outside experts who hold dissenting views to be heard. To Kennedy’s supporters, this is precisely what Americans were promised but rarely received during the pandemic years.
Critics, including the media, have tried to frame the hearing as proof that Kennedy is politicizing science. But those who back him say the opposite is true. They argue that the pandemic revealed just how politicized public health had already become, with ever-shifting mask mandates, school closures that devastated children, and vaccine policies that punished dissent while failing to stop transmission. By cleaning house, Kennedy is confronting that reality rather than covering it up.
The hearing also underscores the political risks Kennedy has taken. He was confirmed with bipartisan support, including from Republican Sen. Bill Cassidy of Louisiana, who chairs the committee holding Wednesday’s session. Cassidy has since expressed concern about Kennedy’s direction, reflecting the uneasy coalition that brought him into office. Some lawmakers who once championed reform now appear unsettled by how forcefully Kennedy has moved. That tension will likely play out in the questioning, as senators try to balance their own records with the growing demands of their constituents for accountability in public health.
For Kennedy’s critics, the testimony of Monarez and Houry will be held up as evidence that the administration is overreaching. For his supporters, their presence will be seen as confirmation that the bureaucracy is unwilling to give up control, even after years of failure.
The controversy over Monarez’s firing has drawn heavy media coverage, but Kennedy has remained focused on his broader agenda. He has described his changes at CDC and HHS as part of a mission to restore credibility. He points to surveys showing declining confidence in public health institutions and argues that only bold action can reverse the trend. His allies note that while critics warn of politicization, millions of Americans welcome a long-overdue reckoning with institutions that failed them.
The truth of the matter may depend on how Americans judge the results. If vaccine recommendations become more transparent, if conflicts of interest are reduced, and if ordinary citizens feel they can once again trust public health advice, Kennedy’s gamble may prove successful. The Senate hearing will provide a stage for both sides. Monarez and Houry will present their grievances, while Kennedy’s record and reforms will be examined in public. Regardless of the outcome, the session is unlikely to slow the momentum of a secretary who has already shown he is willing to confront both political opponents and bureaucratic inertia.
